HealthEquity’s (HQY) Outperform Rating Reiterated at Barrington Research

Barrington Research reiterated their outperform rating on shares of HealthEquity (NASDAQ:HQY) in a report published on Friday, Benzinga reports. They currently have a $105.00 price target on the stock.

Several other research firms have also recently weighed in on HQY. Bank of America restated a buy rating and issued a $105.00 price target on shares of HealthEquity in a research note on Wednesday, July 3rd. Raymond James boosted their price target on HealthEquity from $100.00 to $105.00 and gave the stock an outperform rating in a research note on Friday, June 7th. Wells Fargo & Company upped their price objective on HealthEquity from $107.00 to $110.00 and gave the company an overweight rating in a research report on Thursday, June 20th. Royal Bank of Canada reiterated an outperform rating and set a $92.00 price objective on shares of HealthEquity in a research report on Tuesday, June 4th. Finally, KeyCorp upped their price objective on HealthEquity from $95.00 to $100.00 and gave the company an overweight rating in a research report on Wednesday, June 5th. One equities research analyst has rated the stock with a hold rating and twelve have given a buy rating to the company’s stock. According to MarketBeat.com, the stock has a consensus rating of Moderate Buy and a consensus target price of $101.67.

HealthEquity Trading Up 3.2 %

NASDAQ HQY opened at $79.56 on Friday. The company has a quick ratio of 4.39, a current ratio of 4.39 and a debt-to-equity ratio of 0.44. HealthEquity has a twelve month low of $61.81 and a twelve month high of $88.26. The firm has a market capitalization of $6.92 billion, a PE ratio of 86.48, a P/E/G ratio of 1.34 and a beta of 0.57. The stock’s 50 day moving average is $77.47 and its 200 day moving average is $79.72.

HealthEquity (NASDAQ:HQY) last announced its quarterly earnings data on Monday, June 3rd. The company reported $0.55 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.47 by $0.08. The business had revenue of $287.60 million during the quarter, compared to analysts’ expectations of $278.78 million. HealthEquity had a return on equity of 7.77% and a net margin of 7.71%. Research analysts forecast that HealthEquity will post 2.12 earnings per share for the current fiscal year.

Insider Buying and Selling at HealthEquity

In other HealthEquity news, Vice Chairman Stephen Neeleman sold 2,080 shares of the business’s stock in a transaction dated Friday, June 7th. The stock was sold at an average price of $85.01, for a total transaction of $176,820.80. Following the completion of the sale, the insider now owns 90,515 shares of the company’s stock, valued at $7,694,680.15. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. In other news, CEO Jon Kessler sold 32,326 shares of the company’s stock in a transaction dated Monday, June 24th. The stock was sold at an average price of $82.83, for a total value of $2,677,562.58. Following the completion of the transaction, the chief executive officer now owns 232,176 shares of the company’s stock, valued at $19,231,138.08. The transaction was disclosed in a filing with the SEC, which is accessible through this hyperlink. Also, Vice Chairman Stephen Neeleman sold 2,080 shares of the company’s stock in a transaction dated Friday, June 7th. The stock was sold at an average price of $85.01, for a total value of $176,820.80. Following the completion of the transaction, the insider now directly owns 90,515 shares of the company’s stock, valued at approximately $7,694,680.15. The disclosure for this sale can be found here. Over the last quarter, insiders sold 77,511 shares of company stock valued at $6,314,446. Company insiders own 2.20% of the company’s stock.

Hedge Funds Weigh In On HealthEquity

A number of hedge funds have recently made changes to their positions in the business. Vanguard Group Inc. boosted its stake in shares of HealthEquity by 1.7% in the first quarter. Vanguard Group Inc. now owns 8,768,632 shares of the company’s stock worth $715,783,000 after acquiring an additional 149,133 shares during the period. Wasatch Advisors LP boosted its stake in shares of HealthEquity by 8.3% in the first quarter. Wasatch Advisors LP now owns 7,409,080 shares of the company’s stock worth $604,803,000 after acquiring an additional 569,249 shares during the period. Motley Fool Asset Management LLC boosted its stake in shares of HealthEquity by 3,001.0% in the first quarter. Motley Fool Asset Management LLC now owns 3,762,064 shares of the company’s stock worth $307,097,000 after acquiring an additional 3,640,748 shares during the period. Clearbridge Investments LLC boosted its stake in shares of HealthEquity by 1.9% in the second quarter. Clearbridge Investments LLC now owns 2,377,204 shares of the company’s stock worth $204,915,000 after acquiring an additional 43,491 shares during the period. Finally, Mackenzie Financial Corp boosted its stake in shares of HealthEquity by 16.0% in the second quarter. Mackenzie Financial Corp now owns 2,364,521 shares of the company’s stock worth $203,822,000 after acquiring an additional 325,906 shares during the period. Institutional investors own 99.55% of the company’s stock.

About HealthEquity

HealthEquity, Inc provides technology-enabled services platforms to consumers and employers in the United States. The company offers cloud-based platforms for individuals to make health saving and spending decisions, pay healthcare bills, receive personalized benefit information, earn wellness incentives, grow their savings, and make investment choices; and health savings accounts.